Exact FDA event identifier

Event 91980

14 recalled-product records grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: March 20, 2023
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: RemedyRepack Inc.

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

14 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 14

Aripiprazole 5mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-2921-03

D-0490-2023

Recall number: D-0490-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 3 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: J0620431-052322, Exp. Date 05/31/23

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 2 of 14

Atorvastatin 10 mg tablets, packaged in a) 30-count bottles (NDC 70518-1946-00) and b) 90-count bottles (NDC 70518-1946-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

D-0491-2023

Recall number: D-0491-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 3,497 bottles, b) 729 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: a) J0679046-020123, Exp. Date 02/28/2024; J0669807-122122, Exp. Date 01/31/2024; J0662695-112222, Exp. Date 12/31/2023; J0654076-101822, J0654076-101822, Exp. Date 11/30/2023; J0642765-082922, Exp. Date 09/30/2023 Lot #: b) B1672408-050322, B1765902-071322, B1769634-071622, Exp. Date 04/30/2023; B1776907-072122, Exp. Date 09/30/2023; B1836636-090322, Exp. Date 11/30/2023; B1870344-092422, Exp. Date 01/31/2024; B1908452-101522, B1966455-111722, B2043099-010423, Exp. Date 05/31/2024

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 3 of 14

Doxazosin 2 mg tablets, packaged in a) 30-count (NDC 70518-1560-00) and b) 90-count bottles (NDC 70518-1560-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

D-0492-2023

Recall number: D-0492-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 58 bottles, b) 6 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: a) J0665197-120522, Exp. Date 12/31/2023; J0642497-082722, Exp. Date 09/30/2023 J0638552-080922, Exp. Date 08/31/2023. Lot #: b) B1808799-081622, Exp. Date 05/31/2024

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 4 of 14

Glimepiride 2 mg tablets, packaged in a) 30-count bottles (NDC 70518-0405-03), b) 90-count bottles (NDC 70518-0405-00) and c)180-count bottles (NDC 70518-0405-02), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701

D-0493-2023

Recall number: D-0493-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 147 bottles, b)70 bottles, c) 3 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: a) J0674153-010923, Exp. Date 01/31/2024; J0649447-092822, Exp. Date 10/31/2023; J0644887-090722, Exp. Date 09/30/2023; J0627309-062222, Exp. Date 06/30/2023; J0622569-060222, Exp. Date 06/30/2023. b) B1646259-041222, Exp. Date 04/30/2023; B2032846-122722, Exp. Date 01/31/2025 B2018675-121722, Exp. Date 05/31/2025; B1708230-060122, B1709748-060122, Exp. Date 06/30/2023; B1692572-051822, Exp. Date 05/31/2023; B1803110-081122, Exp. Date 12/31/2024. c) B1820672-082422, B1814883-082022, Exp. Date 09/30/2024.

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 5 of 14

Ropinirole 0.5 mg tablets, packaged in 90-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-2439-00.

D-0494-2023

Recall number: D-0494-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 17 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: B1789178-080122, Exp. Date 07/31/2023; B1675475-050522, Exp. Date 05/31/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 6 of 14

Rosuvastatin 5mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-3519-00.

D-0495-2023

Recall number: D-0495-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 399 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: J0668398-121422, Exp. Date 12/31/2023; J0661225-111522, J0654053-101822 Exp. Date 11/30/2023; J0646383-091422, Exp. Date 09/30/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 7 of 14

Simvastatin 10 mg tablets, packaged in a) 30-count bottles (NDC 70518-0064-01) and b) 90-count bottles (NDC 70518-0064-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701

D-0496-2023

Recall number: D-0496-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 1,262 bottles, b) 95 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: a) J0675206-011223, J0669260-121922, Exp. Date 01/31/2024; J0656820-103122, J0647161-091722, Exp. Date 09/30/2023 Exp. Date 11/30/2023; J0621491-052722, Exp. Date 06/30/2023; J0638138-080822, Exp. Date 08/31/2023, J0610887-041122, Exp. Date 04/30/2023. Lot # b) B1887315-100422, Exp. Date 02/28/2024; B1829906-083122, B1769715-071622, Exp. Date 09/30/2023; B1906605-101422, Exp. Date 02/28/2024; B1965118-111622, Exp. Date 02/28/2025.

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 8 of 14

Tadalafil 5 mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-2972-00

D-0497-2023

Recall number: D-0497-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 16 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: B1635780-040522, Exp. Date 04/30/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 9 of 14

Atorvastatin 20 mg tablets, packaged in a) 30-count bottles (NDC 70518-1977-00) and b)90-count bottles (NDC 70518-1977-01), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

D-0498-2023

Recall number: D-0498-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 3,426 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot #: a) J0659819-110922, Exp. Date 11/30/2023; J0649932-093022, J0649917-093022 Exp. Date 10/31/2023, B2010060-121222, Exp. Date 03/31/24 Lot #: b) B1708575-060122, Exp. Date 05/31/2023; B1879236-092922, Exp. Date 12/31/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 10 of 14

Ropinirole 2mg tablets, packaged in 180-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC70518-2750-00

D-0499-2023

Recall number: D-0499-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 3 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot#: B1630017-040122, Exp. Date 04/30/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 11 of 14

Rosuvastatin 5mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-3519-00

D-0500-2023

Recall number: D-0500-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: 132 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot#: J0668398-121422, Exp. Date 12/31/2023; J0661225-111522, J0654053-101822 Exp. Date 11/30/2023; J0646383-091422, Exp. Date 09/30/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 12 of 14

Rosuvastatin 10mg tablets, packaged in a) 30-count bottles (NDC 70518-0375-03 and 70518-0375-01) and b) 90-count bottles (NDC 70518-0375-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

D-0501-2023

Recall number: D-0501-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 399 bottles, b)445 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot#: a) NDC 70518-0375-03: J0674788-011123, Exp. Date 01/31/2024; J0664118-112922 J0664118-112922, Exp. Date 12/31/2023; J0653727-101722, Exp. Date 10/31/2023. NDC 70518-0375-01: B2057931-011223, Exp. Date 07/31/2025 b) Lot #: B2075815-012523, Exp. Date 09/30/2025; B2011634-121322, Exp. Date 07/31/2025 B1970205-112022, Exp. Date 06/30/2024; B1862598-092022, Exp. Date 03/31/2024; B2077226-012523, B2070444-012023, Exp. Date 07/31/2025.

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 13 of 14

Rosuvastatin 40mg tablets, packaged in a) 45-count bottles (NDC 70518-1311-01), and b) 90-count bottles (NDC 70518-0484-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701.

D-0502-2023

Recall number: D-0502-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: a) 76 bottles, b)151 bottles

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot # a): B2038806-123022, B2014185-121422, B1925528-102522, Exp. Date 07/31/2025. Lot #: b): B2080829-012823, B1938007-110222, B2038746-123022, Exp. Date 07/31/2025.

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States

drug · product 14 of 14

Simvastatin 40 mg tablets, packaged in a) 30-count bottles (NDC 70518-0060-01) and b) 90-count bottles (NDC 70518-0060-00), Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701

D-0503-2023

Recall number: D-0503-2023
Initiated: March 20, 2023
Classification: Class II
Status: Terminated
Recalling firm: RemedyRepack Inc.
Quantity: Unavailable

App-derived interpretation

Manufacturing or process control reason.manufacturing_process_control · v1.0.0

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

cGMP Deviations

Code information

Lot # a): J0656821-103122, Exp. Date 11/30/2023; J0638547-080922, Exp. Date 08/31/2023; J0633575-071822, Exp. Date 07/31/2023 Lot #: b): B1965081-111622, Exp. Date 03/31/2025; B1857922-091922, B1765298-071322, B1786319-072922, B1706842-053122, Exp. Date 04/30/2023; B2003311-120822, Exp. Date 04/30/2025; B1955679-111122, Exp. Date 02/28/2025; B1878942-092922, Exp. Date 11/30/2024; B1823203-082622. Exp. Date 10/31/2024; B1706843-053122, Exp. Date 05/31/2023

Distribution pattern

RemedyRepack distributed product to consignees nationwide within the United States